Affinivax Overview
- Year Founded
-
2014

- Status
-
Acquired/Merged
- Employees
-
200

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3B
- Investors
-
1
Affinivax General Information
Description
Operator of a vaccine development company intended to enhance the depth and breadth of protection against challenging infectious diseases. The company's vaccine development features a patented approach to achieve high-affinity binding of two key immunogenic components, polysaccharide and protein antigens so that both components are able to drive abroad and protective B-cell and T-cell immune response in a single vaccine, enabling doctors to develop preventive and therapeutic vaccines that provide broader protection against infectious and other immune-mediated diseases.
Contact Information
Website
www.affinivax.comCorporate Office
- 301 Binney Street
- Suite 302
- Cambridge, MA 02142
- United States
Corporate Office
- 301 Binney Street
- Suite 302
- Cambridge, MA 02142
- United States
Affinivax Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Merger/Acquisition | 15-Aug-2022 | $3B | Completed | Clinical Trials - General | ||
5. Later Stage VC (Series C) | 03-May-2021 | Completed | Clinical Trials - General | |||
4. Later Stage VC (Series B) | 23-Apr-2020 | Completed | Clinical Trials - General | |||
3. Early Stage VC (Series A) | 05-Jan-2018 | Completed | Clinical Trials - General | |||
2. Early Stage VC | 05-Feb-2016 | $2.5M | $6.5M | Completed | Clinical Trials - General | |
1. Seed Round | 30-Oct-2014 | $4M | $4M | Completed | Clinical Trials - General |
Affinivax Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | ||||||||
Series C-1 | ||||||||
Series B | 8,452,884 | $0.000100 | $14.22 | $14.22 | 1x | $14.22 | 24.55% | |
Series A | 3,068,305 | $0.000100 | $2.28 | $2.28 | 1x | $2.28 | 8.93% |
Affinivax Comparisons
Industry
Financing
Details
Affinivax Competitors (31)
One of Affinivax’s 31 competitors is Micron Biomedical, a Venture Capital-Backed company based in Atlanta, GA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Micron Biomedical | Venture Capital-Backed | Atlanta, GA | ||||
AgomAb | Venture Capital-Backed | Antwerp, Belgium | ||||
Alzheon | Venture Capital-Backed | Framingham, MA | ||||
Quince Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Affinivax Patents
Affinivax Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230091255-A1 | Multivalent pneumococcal vaccines | Active | 09-Sep-2021 | ||
CA-3231684-A1 | Multivalent pneumococcal vaccines | Pending | 09-Sep-2021 | ||
AU-2022342080-A1 | Multivalent pneumococcal vaccines | Pending | 09-Sep-2021 | ||
US-12036276-B2 | Multivalent pneumococcal vaccines | Active | 09-Sep-2021 | ||
US-20240398924-A1 | Multivalent pneumococcal vaccines | Pending | 09-Sep-2021 | A61K39/092 |
Affinivax Signals
Affinivax Former Investors (16)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | Minority | ||
BlackRock | Asset Manager | Minority | ||
CARB-X | University | Minority | ||
Citadel Enterprise Americas | Hedge Fund | Minority |
Affinivax FAQs
-
When was Affinivax founded?
Affinivax was founded in 2014.
-
Where is Affinivax headquartered?
Affinivax is headquartered in Cambridge, MA.
-
What is the size of Affinivax?
Affinivax has 200 total employees.
-
What industry is Affinivax in?
Affinivax’s primary industry is Drug Discovery.
-
Is Affinivax a private or public company?
Affinivax is a Private company.
-
What is the current valuation of Affinivax?
The current valuation of Affinivax is
. -
What is Affinivax’s current revenue?
The current revenue for Affinivax is
. -
How much funding has Affinivax raised over time?
Affinivax has raised $359M.
-
Who are Affinivax’s investors?
Bain Capital Life Sciences, Bill & Melinda Gates Foundation, BlackRock, CARB-X, and Citadel Enterprise Americas are 5 of 16 investors who have invested in Affinivax.
-
Who are Affinivax’s competitors?
Micron Biomedical, AgomAb, Alzheon, Quince Therapeutics, and Kite Pharma are some of the 31 competitors of Affinivax.
-
When was Affinivax acquired?
Affinivax was acquired on 15-Aug-2022.
-
Who acquired Affinivax?
Affinivax was acquired by GSK.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »